Interleukin-21 increases direct cytotoxicity and IFN-γ production of Ex Vivo expanded nk cells towards breast cancer cells

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 839-846

  Park, Young Ki ^a   Shin, Dong Jun ^b   Cho, Duck ^a,b,c   Kim, Sang Ki ^b,d   Lee, Je Jung ^a   Shin, Myung Geun ^a   Ryang, Dong Wook ^a   Lee, Ji Shin ^a,c   Park, Min Ho ^a,b,c   Yoon, Jung Han ^a   Jegal, Young Jong ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^c Chonnam National University   (South Korea)

^d Kongju National University   (South Korea)

Author keywords

ADCC; Breast cancer; Cytotoxicity; IL 21; MCF 7; NK cells; SKBR3; T47D cell lines

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL; CELL EXPANSION; CELL ISOLATION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; IRRADIATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; KILLER CELLS, NATURAL;

EID: 84863365408     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
2. Valabrega G, Montemurro F and Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977-984, 2007. (Pubitemid 47050487)
3. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Gamier J, Jeannin JF and Coudert B: Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267, 2006. (Pubitemid 43151545)
4. Alderson KL and Sondel PM: Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 379123, 2011.
5. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446, 2000. (Pubitemid 30208162)
6. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H and Matsumoto Y: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817, 2002. (Pubitemid 35204740)
7. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H and Fujii H: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120: 781-787, 2007. (Pubitemid 46175397)
8. Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N and Toi M: Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother 63: 703-706, 2009.
9. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T and Fujii H: Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 102: 520-529, 2010.
10. Parihar R, Dierksheide J, Hu Y and Carson WE: IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110: 983-992, 2002.
11. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S and Carson WE, 3rd: Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 177: 120-129, 2006. (Pubitemid 43939123)
12. Brady J, Carotta S, Thong RP, Chan CJ, Hayakawa Y, Smyth MJ and Nutt SL: The interactions of multiple cytokines control NK cell maturation. J Immunol 185: 6679-6688, 2010.
13. Cho D, Kim S and Carson III WE: NK cell-based immunotherapy for treating cancer. Will it be promising? Korean J Hematol 46: 3-5, 2011.
14. Stein MN, Shin J, Gudzowaty O, Bernstein AM and Liu JM: Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res 26: 1759-1763, 2006. (Pubitemid 43989429)
15. Imai C, Iwamoto S and Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383, 2005. (Pubitemid 40967217)
16. Cho D and Campana D: Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 29: 89-96, 2009.
17. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
18. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG and Dilber MS: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111: 3155-3162, 2008.
19. Gong W, Xiao W, Hu M, Weng X, Qian L, Pan X and Ji M: Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. Tissue Antigens 76: 467-475, 2010.
20. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ and Lee DA Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7: e30264. 2012.
21. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH and Campana D: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69: 4010-4017, 2009.
22. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H and Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16: 3901-3909, 2010.
23. Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K and Mann DL: Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res 29: 134-146, 2010.
24. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S and Carson WE, 3rd: The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 13: 6419-6428, 2007. (Pubitemid 350075032)
25. Berg M, Lundqvist A, McCoy P Jr., Samsel L, Fan Y, Tawab A and Childs R: Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11: 341-355, 2009.
26. Lyon E, Millson A, Lowery MC, Woods R and Wittwer CT: Quantification of HER2lneu gene amplification by competitive per using fluorescent melting curve analysis. Clin Chem 47: 844-851, 2001. (Pubitemid 32398035)
27. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, Navabi H, Miller KD and Balaton AJ: A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 117: 81-89, 2002. (Pubitemid 34052476)
28. Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ and Crown J: Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol online Nov 5. 2011.
29. Park SY, Seol JW, Lee YJ, Cho JH, Kang HS, Kim IS, Park SH, Kim TH, Yim JH, Kim M, Billiar TR and Seol DW: IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem 271: 4222-4228, 2004. (Pubitemid 39506751)
30. Shin EC, Ahn JM, Kim CH, Choi Y, Ahn YS, Kim H, Kim SJ and Park JH: IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int J Cancer 93: 262-268, 2001. (Pubitemid 32574283)
31. Suk K, Chang I, Kim YH, Kim S, Kim JY, Kim H and Lee MS: Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J Biol Chem 276: 13153-13159, 2001.
32. Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP and Ferrini S: IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 172: 1540-1547, 2004. (Pubitemid 38116798)